FD-IN-1
| 中文名称 | FD-IN-1 |
|---|---|
| 中文同义词 | 化合物 T11269;化合物 FD-IN-1;FD 抑制剂 1 |
| 英文名称 | FD-IN-1 |
| 英文同义词 | FD-IN-1;Benzeneacetic acid, 2-[[3'-[(1S)-1-amino-2-hydroxyethyl][1,1'-biphenyl]-3-yl]methoxy]-;(S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid;FDIN1,FD IN 1 |
| CAS号 | 1646682-14-5 |
| 分子式 | C23H23NO4 |
| 分子量 | 377.43 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 1646682-14-5.mol |
| 结构式 |  |
FD-IN-1 性质
| 沸点 | 629.4±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.251±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 酸度系数(pKa) | 4.14±0.10(Predicted) |
| 颜色 | 白色至米白色 |
FD-IN-1 (Compound 12) exhibits functional inhibition of AP activation (IC 50 =0.26 μM) in vitro in a membrane attack complex (MAC) deposition assay using 50% human whole blood (WB).
FD-IN-1 (Compound 12) demonstrates systemic suppression of AP activation in a lipopolysaccharide-induced alternative complement pathway (AP) activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.
FD-IN-1 (Compound 12) exhibits high oral bioavailability (C57BL6 mice 83%, Beagle dogs 70%) following oral administration (mice and dogs 10 mg/kg).
FD-IN-1 (Compound 12) exhibits terminal elimination half-lives (C57BL6 mice 1.6 h and Beagle dogs 3.8 h) following intravenous administration (mice and dogs 1 mg/kg).
| Animal Model: | Human FD knock-in mice |
| Dosage: | 3 and 10 mg/kg |
| Administration: | Oral gavage |
| Result: | The AP pathway was fully inhibited for up to 10 h at the 10 mg/kg dose. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-128570 | FD-IN-1 | 1646682-14-5 | 1 mg | 1590元 |
| 2025/12/22 | HY-128570 | FD-IN-1 FD-IN-1 | 1646682-14-5 | 5mg | 3500元 |